Sandro Nuciforo

Basel, BS 4031, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors.

Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors.

Journal: Cell reports
Published: January 06, 2026

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.

Journal: Gastro hep advances
Published: July 03, 2024

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.

Journal: EBioMedicine
Published: February 06, 2024

Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC.

Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC.

Journal: Hepatology communications
Published: January 23, 2024

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.

Journal: Nature communications
Published: July 13, 2023

Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.

Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.

Journal: NPJ precision oncology
Published: February 23, 2023

Arginine reprograms metabolism in liver cancer via RBM39.

Arginine reprograms metabolism in liver cancer via RBM39.

Journal: Cell
Published: December 09, 2022

Human-correlated genetic models identify precision therapy for liver cancer.

Human-correlated genetic models identify precision therapy for liver cancer.

Journal: Nature
Published: May 09, 2022

IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.

IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.

Journal: Gut
Published: February 11, 2022

Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report.

Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report.

Journal: Communications medicine
Published: September 21, 2021

Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.

Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.

Journal: Molecular oncology
Published: July 20, 2021

Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.

Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.

Journal: Nature communications
Published: May 10, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026